Your browser doesn't support javascript.
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses.
Ortega, Natalia; Ribes, Marta; Vidal, Marta; Rubio, Rocío; Aguilar, Ruth; Williams, Sarah; Barrios, Diana; Alonso, Selena; Hernández-Luis, Pablo; Mitchell, Robert A; Jairoce, Chenjerai; Cruz, Angeline; Jimenez, Alfons; Santano, Rebeca; Méndez, Susana; Lamoglia, Montserrat; Rosell, Neus; Llupià, Anna; Puyol, Laura; Chi, Jordi; Melero, Natalia Rodrigo; Parras, Daniel; Serra, Pau; Pradenas, Edwards; Trinité, Benjamin; Blanco, Julià; Mayor, Alfredo; Barroso, Sonia; Varela, Pilar; Vilella, Anna; Trilla, Antoni; Santamaria, Pere; Carolis, Carlo; Tortajada, Marta; Izquierdo, Luis; Angulo, Ana; Engel, Pablo; García-Basteiro, Alberto L; Moncunill, Gemma; Dobaño, Carlota.
  • Ortega N; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Ribes M; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Vidal M; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Rubio R; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Aguilar R; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Williams S; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Barrios D; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Alonso S; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Hernández-Luis P; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Mitchell RA; Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • Jairoce C; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Cruz A; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Jimenez A; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
  • Santano R; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Méndez S; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Lamoglia M; Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain.
  • Rosell N; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Llupià A; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Puyol L; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Chi J; School of Health Sciences TecnoCampus Universitat Pompeu Fabra, Mataró, Spain.
  • Melero NR; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Parras D; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Serra P; Department of Preventive Medicine and Epidemiology, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.
  • Pradenas E; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Trinité B; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Blanco J; Biomolecular screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Mayor A; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Barroso S; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Varela P; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, Badalona, Catalonia, Spain.
  • Vilella A; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, Badalona, Catalonia, Spain.
  • Trilla A; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, Badalona, Catalonia, Spain.
  • Santamaria P; University of Vic-Central University of Catalonia (UVic-UCC), Vic, Catalonia, Spain.
  • Carolis C; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Tortajada M; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
  • Izquierdo L; Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain.
  • Angulo A; Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Engel P; Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • García-Basteiro AL; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Moncunill G; Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain.
  • Dobaño C; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
Nat Commun ; 12(1): 4740, 2021 08 06.
Article in English | MEDLINE | ID: covidwho-1345557
ABSTRACT
Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronavirus 229E, Human / Antibodies, Neutralizing / Coronavirus NL63, Human / SARS-CoV-2 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-24979-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronavirus 229E, Human / Antibodies, Neutralizing / Coronavirus NL63, Human / SARS-CoV-2 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-24979-9